| pioglitazone / Generic mfg. |
NCT00521742: Efficacy of Pioglitazone Compared to Glyburide in Treating Subjects With Type 2 Diabetes Mellitus and Mild Cardiac Disease |
|
|
| Completed | 3 | 300 | US | Pioglitazone, Actos, AD4833, Glyburide | Takeda, Takeda Pharmaceuticals North America, Inc. | Diabetes Mellitus | 01/03 | 01/03 | | |
NCT00521820: Safety Comparison of Pioglitazone and Glyburide in Type 2 Diabetes Subjects With Mild to Moderate Congestive Heart Failure |
|
|
| Terminated | 3 | 518 | US | Pioglitazone, Actos, AD-4833, Glyburide | Takeda | Diabetes Mellitus | 10/03 | 10/03 | | |
NCT00331487: Study to Compare Pioglitazone and Rosiglitazone in Subjects With Type 2 Diabetes Mellitus and Dyslipidemia |
|
|
| Completed | 3 | 719 | US | Pioglitazone, Actos, AD4833, Rosiglitazone | Takeda, Eli Lilly and Company | Diabetes Mellitus | 03/04 | 03/04 | | |
| Completed | 3 | 4373 | Europe | Pioglitazone, Actos, AD4833, Placebo | Takeda, Eli Lilly and Company | Diabetes Mellitus | 01/05 | 01/05 | | |
NCT00240370: A Study to Evaluate Combining Metformin With Muraglitazar or Pioglitazone in Type 2 Diabetics |
|
|
| Completed | 3 | 1159 | US, Canada, RoW | Muraglitazar | Bristol-Myers Squibb | Type 2 Diabetes | 03/05 | | | |
NCT00086502: Pioglitazone Add-on Study in Patients With Type 2 Diabetes Mellitus |
|
|
| Completed | 3 | 353 | US | Comparator: Sitagliptin, Januvia, Comparator: Placebo, Comparator: Pioglitazone, ACTOS, Metformin | Merck Sharp & Dohme LLC | Diabetes Mellitus, Type 2 | 11/05 | 11/05 | | |
| Completed | 3 | 527 | US | vildagliptin | Novartis Pharmaceuticals | Diabetes Mellitus, Type 2 | 01/06 | 01/06 | | |
NCT00106704: Sulfonylurea Add-on Study in Patients With Type 2 Diabetes Mellitus (0431-035) |
|
|
| Completed | 3 | 441 | US | Comparator: Sitagliptin, Comparator: Placebo, Comparator: Pioglitazone | Merck Sharp & Dohme LLC | Diabetes Mellitus, Type 2 | 06/06 | 01/07 | | |
NCT00138554: Extension to a Study on the Efficacy and Safety of Vildagliptin in Combination With Pioglitazone in Patients With Type 2 Diabetes |
|
|
| Completed | 3 | 318 | US | vildagliptin, pioglitazone | Novartis | Diabetes Mellitus, Type 2 | 07/06 | 07/06 | | |
NCT00106808: Study of Muraglitazar Versus Pioglitazone in Type 2 Diabetes |
|
|
| Completed | 3 | 1440 | US, Canada, RoW | Muraglitazar, Pioglitazone | Bristol-Myers Squibb, Merck Sharp & Dohme LLC | Type 2 Diabetes Mellitus | 08/06 | 08/06 | | |
| Terminated | 3 | 1450 | US, Canada, Europe, RoW | Galida | AstraZeneca | Diabetes Mellitus, Type 2 | 10/06 | 10/06 | | |
| Terminated | 3 | 1100 | US, Canada, Europe, RoW | Tesaglitazar, Galida, Pioglitazone, Actos | AstraZeneca | Diabetes Mellitus, Type 2 | 12/06 | 12/06 | | |
| Completed | 3 | 588 | US, Europe | vildagliptin | Novartis | Diabetes Mellitus, Type 2 | 02/07 | | | |
NCT00376181: Efficacy, Safety and Tolerability of Pioglitazone-Azilsartan in Subjects With Type 2 Diabetes Mellitus |
|
|
| Terminated | 3 | 96 | US, RoW | Pioglitazone and Azilsartan, Actos, AD-4833, TAK-536, Pioglitazone | Takeda | Type 2 Diabetes | 05/07 | 05/07 | | |
NCT01124656: Safety and Tolerability of Pioglitazone-Azilsartan in Subjects With Type 2 Diabetes |
|
|
| Terminated | 3 | 26 | US | Pioglitazone-Azilsartan, Pioglitazone, Actos, Azilsartan, AD-4833, TAK-536 | Takeda | Diabetes Mellitus, Type 2 | 05/07 | 05/07 | | |
| Completed | 3 | 493 | US, Europe, RoW | Alogliptin and pioglitazone, SYR110322, Alogliptin, AD-4833, Pioglitazone, Actos, SYR-322 | Takeda | Diabetes Mellitus | 08/07 | 08/07 | | |
NCT00295633: A Study Assessing Saxagliptin Treatment in Type 2 Diabetic Subjects Who Are Not Controlled With TZD Therapy Alone |
|
|
| Completed | 3 | 565 | US, Canada, RoW | Saxagliptin, BMS-477118, Placebo, pioglitazone, rosiglitazone, metformin | AstraZeneca | Diabetes Mellitus, Type 2 | 10/07 | 10/08 | | |
NCT00396227: Safety and Efficacy of Vildagliptin vs. Thiazolidinedione as add-on Therapy to Metformin in Patients With Type 2 Diabetes Not Controlled With Metformin Alone |
|
|
| Completed | 3 | 2665 | US | vildagliptin, Galvus, thiazolidinedione (TZD), Actos (pioglitazone), Avandia (rosiglitazone) | Novartis Pharmaceuticals | Diabetes Mellitus, Type 2 | 10/07 | | | |
| Completed | 3 | 655 | US, Europe, RoW | Alogliptin, SYR-322, Pioglitazone, Actos, AD4833, Placebo | Takeda | Diabetes Mellitus | 02/08 | 02/08 | | |
| Completed | 3 | 418 | Europe | Pioglitazone and Metformin, ACTOS®, AD4833, Metformin | Takeda | Diabetes Mellitus | 02/08 | 02/08 | | |
NCT00372060: MK0431 (Sitagliptin) Pioglitazone Add-on Study for Patients With Type 2 Diabetes Mellitus (0431-055)(COMPLETED) |
|
|
| Completed | 3 | 134 | Japan | sitagliptin phosphate, MK0431, Comparator: sitagliptin phosphate (MK0431), Comparator: pioglitazone, Comparator: placebo (unspecified) | Merck Sharp & Dohme LLC | Type 2 Diabetes Mellitus | 02/08 | 02/08 | | |
| Completed | 3 | 1554 | US, Europe, RoW | Alogliptin, SYR-322, Alogliptin placebo, Pioglitazone, ACTOS®, Pioglitazone placebo | Takeda | Type 2 Diabetes Mellitus | 03/08 | 03/08 | | |
|
|
NCT00411892: Effect of Inhaled Insulin (AERx® iDMS) on Blood Glucose Control in Type 2 Diabetes |
|
|
| Terminated | 3 | 196 | US | pioglitazone, inhaled human insulin, NN1998 | Novo Nordisk A/S | Diabetes, Diabetes Mellitus, Type 2 | 03/08 | 03/08 | | |
| Completed | 3 | 520 | US | sitagliptin 100 mg q.d./pioglitazone 30 mg q.d, Comparator: placebo to match sitagliptin 100 mg q.d./pioglitazone 30 mg q.d. | Merck Sharp & Dohme LLC | Type 2 Diabetes Mellitus | 06/08 | 06/08 | | |
| Completed | 3 | 91 | Europe | Pioglitazone and Glimepiride, ACTOS®, Glimepiride | Takeda | Diabetes Mellitus | 12/08 | 12/08 | | |
| Completed | 3 | 389 | Japan, Europe | placebo + pioglitazone (30 mg), Linagliptin + pioglitazone (30 mg) | Boehringer Ingelheim | Diabetes Mellitus, Type 2 | 06/09 | | | |
NCT00532935: MK0431A vs. Pioglitazone in Patients With Type 2 Diabetes Mellitus (0431A-066) |
|
|
| Completed | 3 | 517 | NA | sitagliptin phosphate (+) metformin hydrochloride, Janumet, Comparator: pioglitazone, pioglitazone | Merck Sharp & Dohme LLC | Type 2 Diabetes Mellitus | 10/09 | 10/09 | | |
| Completed | 3 | 597 | Europe, RoW | dapagliflozin, Glimepiride, Amaryl, metformin hydrochloride, Glucophage, pioglitazone hydrochloride, Actos, Rosiglitazone, Avandia | AstraZeneca, Bristol-Myers Squibb | Type 2 Diabetes | 11/09 | 05/10 | | |
|
|
|
|
|
| Completed | 3 | 71 | Europe | Alogliptin and Pioglitazone, alogliptin, SYR110322, Actos, AD-4833, SYR-322, Alogliptin, Placebo | Takeda | Diabetes Mellitus | 12/09 | 12/09 | | |
|
|
|
| Completed | 3 | 972 | US, Canada, RoW | Dapagliflozin, BMS-512148, Placebo matching Dapagliflozin, Thiazolidinedione (Pioglitazone) | AstraZeneca, Astra Zeneca, Bristol-Myers Squibb | Type 2 Diabetes | 01/10 | 06/10 | | |
|
|
|
NCT00541450: A Study to Evaluate the Efficacy and Safety of Sitagliptin and MK0431A in Comparison to a Commonly Used Medication in Patients With Type 2 Diabetes (0431-068)(COMPLETED) |
|
|
| Completed | 3 | 492 | US | Comparator: sitagliptin phosphate (sitagliptin), MK0431, Januvia™, sitagliptin phosphate (+) metformin hydrochloride, MK-0431A, Janumet™, Comparator: pioglitazone, Actos®, Matching placebo to pioglitazone, Matching placebo to sitagliptin, Matching Placebo to Sita/Met FDC | Merck Sharp & Dohme LLC | Type 2 Diabetes Mellitus | 01/10 | 01/10 | | |
|
|
| Completed | 3 | 602 | US | Pioglitazone, Actos, Placebo | The University of Texas Health Science Center at San Antonio, University of Texas, Takeda Pharmaceuticals North America, Inc. | Impaired Glucose Tolerance, Type 2 Diabetes | 04/10 | 04/10 | | |
|
|
|
NCT00970424 / 2009-012598-37: Safety and Efficacy of Dutogliptin in Patients With Type 2 Diabetes Mellitus (T2DM) on Background Therapy With Pioglitazone |
|
|
| Terminated | 3 | 252 | US, Europe, RoW | Placebo, Dutogliptin | Forest Laboratories, Phenomix | Diabetes Mellitus, Type II | 08/10 | | | |
| Completed | 3 | 447 | Europe, RoW | insulin degludec/insulin aspart, biphasic insulin aspart 30 | Novo Nordisk A/S | Diabetes, Diabetes Mellitus, Type 2 | 08/10 | 08/10 | | |
|
|
|
NCT01156597: Effects of Pioglitazone on High-density Lipoprotein (HDL) Function in Persons With Diabetes |
|
|
| Completed | 3 | 30 | US | pioglitazone, ACTOS | University of Miami, Takeda Pharmaceuticals North America, Inc. | Type 2 Diabetes Mellitus | 09/10 | 09/10 | | |
NCT00722371: MK0431 and Pioglitazone Co-Administration Factorial Study in Patients With Type 2 Diabetes Mellitus (0431-102 AM2) |
|
|
| Completed | 3 | 1615 | US | Sitagliptin phosphate, Januvia, Tesavel, Xelevia, Ristaben, Pioglitazone hydrochloride, Actos, Matching placebo to sitagliptin, Matching placebo to pioglitazone, Metformin | Merck Sharp & Dohme LLC | Type 2 Diabetes Mellitus | 10/10 | 03/11 | | |
| Completed | 3 | 756 | US, Canada, Europe, RoW | pioglitazone, taspoglutide | Hoffmann-La Roche | Diabetes Mellitus Type 2 | 11/10 | 11/10 | | |
| Completed | 3 | 484 | US, Canada, Europe, RoW | Lixisenatide (AVE0010), Placebo, Pen auto-injector, OptiClik®, Pioglitazone, Metformin | Sanofi | Diabetes Mellitus Type 2 | 06/11 | 06/11 | | |
|
|
NCT01026194: Efficacy and Safety Study of MP-513 in Combination With Thiazolidinedione in Patients With Type 2 Diabetes |
|
|
| Completed | 3 | 204 | Japan | Placebo / Teneli (Teneligliptin) + pio (pioglitazone), Teneli / Teneli + pio | Mitsubishi Tanabe Pharma Corporation | Type 2 Diabetes Mellitus | 06/11 | 06/11 | | |
NCT00849056: Safety and Efficacy of Albiglutide in Type 2 Diabetes |
|
|
| Completed | 3 | 310 | Europe, US, RoW | albiglutide, placebo | GlaxoSmithKline | Diabetes Mellitus, Type 2 | 11/11 | 01/13 | | |
|
|
NCT01289119: Efficacy and Safety of Alogliptin in Participants With Type 2 Diabetes |
|
|
| Completed | 3 | 506 | RoW | Alogliptin, SYR-322, Placebo to alogliptin, Metformin, Fortamet, Glucophage, Glumetza, Pioglitazone, Actos | Takeda | Diabetes Mellitus, Type 2 | 12/11 | 12/11 | | |
|
|
|
NCT00996658 / 2009-013289-20: Linagliptin Versus Placebo in Type 2 Diabetic Patients With Inadequate Glycaemic Control on Metformin in Combination With Pioglitazone |
|
|
| Completed | 3 | 278 | US, Europe, RoW | Placebo, Linagliptin | Boehringer Ingelheim, Eli Lilly and Company | Diabetes Mellitus, Type 2 | 03/12 | | | |
|
|
NCT01106131: Efficacy and Safety of CKD-501 Versus Pioglitazone When Added to Metformin |
|
|
| Completed | 3 | 253 | RoW | CKD-501 0.5mg, Lobeglitazone, Pioglitazone 15mg | Chong Kun Dang Pharmaceutical | Type 2 Diabetes Mellitus | 04/12 | 11/12 | | |
NCT01210001 / 2009-016154-40: Efficacy and Safety of Empagliflozin (BI 10773) in Type 2 Diabetes Patients on a Background of Pioglitazone Alone or With Metformin |
|
|
| Completed | 3 | 499 | US, Canada, Europe, RoW | Placebo, BI 10773 | Boehringer Ingelheim, Eli Lilly and Company | Diabetes Mellitus, Type 2 | 04/12 | | | |
|
|
|
NCT01095666: A Phase III Study of BMS-512148 (Dapagliflozin) in Asian Patients With Type 2 Diabetes Who Are Not Well Controlled on Metformin Alone |
|
|
| Completed | 3 | 1484 | RoW | Dapagliflozin, BMS-512148, Metformin, Glucophage®, Dapagliflozin Placebo, Pioglitazone | AstraZeneca, AstraZeneca, Bristol-Myers Squibb | Type 2 Diabetes | 03/13 | 03/13 | | |
NCT01894568: A Study Comparing Insulin Peglispro With Insulin Glargine as Basal Insulin Treatment |
|
|
| Completed | 3 | 388 | Japan, RoW | Insulin Peglispro, LY2605541, Insulin Glargine, Oral Antihyperglycemic Medications (OAMs), Sulfonylureas, Meglitinides, Dipeptidyl Peptidase-4 (DPP-IV) Inhibitors, Biguanides, α-Glucosidase Inhibitors, Pioglitazone | Eli Lilly and Company | Type 2 Diabetes Mellitus | 04/15 | 04/15 | | |
NCT00353587: Safety and Efficacy Study of Metaglidasen in Type 2 Diabetes in Patients Suboptimally Controlled on Insulin |
|
|
| Completed | 2/3 | 396 | US, RoW | MBX-102, Placebo, Actos | CymaBay Therapeutics, Inc. | Type 2 Diabetes | 11/07 | 11/07 | | |
